Fig. 2

miR-106b facilitates the proliferation of NPCs. a A schematic representation of miR-106b LOF approach. b The number and size of neurospheres were quantified in the miR-106b LOF group, compared to controls. c qPCR analysis of expression levels of miR-106b and transcripts corresponding to markers of proliferating cells (Ki67) and NPCs (Nestin/Sox2) in the miR-106b LOF group, compared to controls. d Immunofluorescence analysis of transduced cells displaying proliferating cell (Ki67/EdU)- and NPC (Nestin/Sox2)-specific immunoreactivities. e Immunofluorescence analysis of transduced cells displaying EdU immunoreactivities. f Quantification of cells displaying immunoreactivities corresponding to proliferating cells and NPCs in the miR-106b LOF group, compared to controls. g A schematic representation of miR-106b GOF approach. h The number and size of neurospheres were quantified in the miR-106b GOF group, compared to controls. i qPCR analysis of expression levels of miR-106b and transcripts corresponding to markers of proliferating cells (Ki67) and NPCs (Nestin/Sox2) in the miR-106b GOF group, compared to controls. j Immunofluorescence analysis of transduced cells displaying proliferating cell (Ki67/EdU)- and NPC (Nestin/Sox2)-specific immunoreactivities. k Immunofluorescence analysis of transduced cells displaying EdU immunoreactivities. l Quantification of cells displaying immunoreactivities corresponding to proliferating cells and NPCs in the miR-106b GOF group, compared to controls. Scale bar, 400 μm (b, h) and 50 μm (d, e, j, k). Data are mean ± SD. ∗∗∗∗p < 0.0001, ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05. Experiments were carried out three times in triplicates for in vitro perturbation